End-of-day quote
Shanghai S.E.
06:00:00 2024-05-09 pm EDT
|
5-day change
|
1st Jan Change
|
52.84
CNY
|
-0.51%
|
|
+4.51%
|
-5.34%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
4,620
|
16,136
|
11,895
|
6,286
|
5,951
|
-
|
Enterprise Value (EV)
1 |
4,620
|
16,136
|
11,895
|
6,286
|
5,951
|
5,951
|
P/E ratio
|
11.9
x
|
51.7
x
|
36.3
x
|
57.5
x
|
19.3
x
|
14.8
x
|
Yield
|
-
|
0.96%
|
0.28%
|
0.54%
|
3.37%
|
4.54%
|
Capitalization / Revenue
|
-
|
13.5
x
|
8.1
x
|
6.45
x
|
3.9
x
|
3
x
|
EV / Revenue
|
-
|
13.5
x
|
8.1
x
|
6.45
x
|
3.9
x
|
3
x
|
EV / EBITDA
|
-
|
42.3
x
|
28.8
x
|
32
x
|
14.4
x
|
11
x
|
EV / FCF
|
-
|
-
|
107,528,297
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
0%
|
-
|
-
|
-
|
Price to Book
|
-
|
11.6
x
|
7.47
x
|
3.84
x
|
3.33
x
|
-
|
Nbr of stocks (in thousands)
|
112,000
|
112,608
|
112,627
|
112,615
|
112,615
|
-
|
Reference price
2 |
41.25
|
143.3
|
105.6
|
55.82
|
52.84
|
52.84
|
Announcement Date
|
3/7/21
|
4/17/22
|
4/24/23
|
4/26/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
1,194
|
1,469
|
975.1
|
1,524
|
1,984
|
EBITDA
1 |
-
|
381.2
|
412.5
|
196.2
|
412.5
|
542.5
|
EBIT
1 |
-
|
359.7
|
371.8
|
119.7
|
356
|
466
|
Operating Margin
|
-
|
30.12%
|
25.32%
|
12.28%
|
23.35%
|
23.49%
|
Earnings before Tax (EBT)
1 |
-
|
360.7
|
370.7
|
119.2
|
356.5
|
467
|
Net income
1 |
225.9
|
311
|
326
|
109.1
|
308
|
403
|
Net margin
|
-
|
26.04%
|
22.2%
|
11.19%
|
20.2%
|
20.31%
|
EPS
2 |
3.480
|
2.770
|
2.910
|
0.9700
|
2.735
|
3.580
|
Free Cash Flow
|
-
|
-
|
110.6
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
7.53%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
26.82%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
33.93%
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
1.380
|
0.3000
|
0.3000
|
1.780
|
2.400
|
Announcement Date
|
3/7/21
|
4/17/22
|
4/24/23
|
4/26/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
111
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
24%
|
22.1%
|
6.71%
|
16.7%
|
19.5%
|
ROA (Net income/ Total Assets)
|
-
|
20.3%
|
18.3%
|
5.83%
|
14.1%
|
16.2%
|
Assets
1 |
-
|
1,533
|
1,779
|
1,873
|
2,192
|
2,488
|
Book Value Per Share
2 |
-
|
12.30
|
14.10
|
14.50
|
15.90
|
-
|
Cash Flow per Share
2 |
-
|
3.320
|
2.510
|
1.650
|
3.460
|
4.560
|
Capex
1 |
-
|
276
|
172
|
122
|
216
|
219
|
Capex / Sales
|
-
|
23.07%
|
11.72%
|
12.49%
|
14.17%
|
11.01%
|
Announcement Date
|
3/7/21
|
4/17/22
|
4/24/23
|
4/26/24
|
-
|
-
|
Last Close Price
52.84
CNY Average target price
70
CNY Spread / Average Target +32.48% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.34% | 824M | | +9.48% | 27.43B | | -30.09% | 3.18B | | -16.08% | 2.53B | | +19.05% | 2.49B | | +11.11% | 2.16B | | -4.24% | 2.03B | | +5.56% | 1.61B | | +2.99% | 1.31B | | +29.73% | 1.29B |
Medical Supplies
|